Forecasted growth for the vaginal and vulval inflammatory diseases treatment market size is US$ 2.96 billion in fiscal year 2023, up from US$ 2.8 billion in fiscal year 2022. The global market is expected to grow at a 5.8% CAGR between 2023 and 2033, reaching a peak of US$ 5.21 billion by the end of that year.
Among the symptoms of vaginal and vulval inflammation are swelling around the vagina, heat when urinating, whitish-gray vaginal discharge, and clumpy vaginal discharge. Candidiasis, a yeast infection, can irritate the vaginal lining. A healthy vagina is made up of bacteria and a small number of yeast cells, but when the ratio of bacteria to yeast changes, these yeast cells or other microorganisms have the potential to grow, causing swelling, acute stinging, and irritation.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16471
According to CDC estimates, 42%-45% of women may experience this illness twice or more per year, and approximately three-fourths of women are expected to develop vaginal and vulval inflammation at least once. This condition is classified as difficult or simple based on its clinical presentation, host characteristics, and response to therapy.
Contacting a gynaecologist or a nurse practitioner is frequently required. Antifungal medications can also be used to treat vaginal and vulval irritation. While most cases of vaginal and vulval inflammation can be treated in a few days, more severe cases may require longer treatment. Over the forecasted period, such factors have increased the demand for treatments for vaginal and vulval inflammations.
Key Takeaways :
- From 2018 to 2022, the market for vaginal and vulval inflammatory diseases grew at a 5.2% CAGR.
- The market for vaginal and vulval inflammatory diseases is expected to grow at a 5.8% CAGR from 2023 to 2033.
- According to projections, vaginal burning will dominate by indication type in 2023, accounting for 53% of total revenue.
- The specialty clinic sector by end-user will be the second-largest segment throughout the forecast period, with a 25% market share in 2023.
- The North American region is expected to grow at a constant CAGR of 6.4% from 2023 to 2033.
- The Asia Pacific vaginal and vulval inflammatory diseases treatment market is expected to grow at a 5.8% CAGR between 2023 and 2033.
“The changing lifestyle among the women, optic for smoking and drinking, increasing incidences of diabetes and increasing research in this domain are the primary drivers of this market.” comments a Future Market Insights analyst.
Competitive Landscape
Some of the top players in the global Parkison’s disease market are:
- Almirall
- VenusConcept
- ThermiGen LLC
- Lutronic
- BTL Group of Companies
- Viveve
- Fotona
- Evofem Biosciences, Inc.
- Spero Therapeutics
- Hologic
- Kyung Hee University Hospital
Some of the recent developments in this domain are:
- The Venus Fiore TM Feminine Health System provides patients with a specialized approach to women’s health. The three applicators in Venus FioreTM are made to tighten labia skin, restore internal vaginal health, and minimize the mons pubis. The revolutionary applicators and features offer the best patient safety, comfort, and cleanliness with single-use disposables, while delivering obvious benefits with no downtime. It is driven by patented (MP)2 technology particularly intended for vulvovaginal health.
Key Segments:
Vaginal And Vulval Inflammatory Diseases Treatment Market By Indication:
- Vaginal Dryness
- Vaginal Burning
- Vaginal Discharge
- Genital Itching
- Recurrent Urinary Tract Infections
- Urinary Incontinence
- Others
Vaginal And Vulval Inflammatory Diseases Treatment Market By Treatment:
- Anti-Itch Medications
- Corticosteroid Ointments
- Anti-Itch Emollients
Vaginal And Vulval Inflammatory Diseases Treatment Market By End User:
- Hospital Pharmacies
- Specialty Clinics
- Others
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16471
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
